

Your request

You requested the following:

We are seeking to understand the initiation of patient treatment with Nivolumab and some additional products in different types of cancer. We would greatly appreciate if you could answer the following questions:

1. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of melanoma?
 - a) Ipilimumab (monotherapy)
 - b) Nivolumab (monotherapy)
 - c) Nivolumab AND Ipilimumab (combination)
 - d) Pembrolizumab
 - e) Any Targeted Therapy (Dabrafenib /Dabrafenib AND Trametinib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
 - f) Other active systemic anti-cancer therapy

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

2. In the last 3 months, how many patients have been initiated* on the following agents for the treatment of renal cell carcinoma?
 - a) Nivolumab (monotherapy)
 - b) Nivolumab + Ipilimumab
 - c) Nivolumab + Cabozantinib
 - d) Avelumab + Axitinib

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

3. In the past 3 months, how many patients have been initiated* on the following agents for the treatment of gastric, gastro-oesophageal junction or oesophageal cancer:
 - a) Nivolumab monotherapy or in combination with Ipilimumab
 - b) Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5 Fluorouracil or Capecitabine)
 - c) Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)

*Patients are considered initiated if they have not been treated in the previous 6 months with any of the drugs that are part of the named regimen.

Our response

1. We do not hold the information requested in points 1a-1f. You may wish to direct your request to Velindre University NHS Trust, which delivers cancer treatment on behalf of the Health Board.
2. We do not hold the information requested in points 2a-2d. You may wish to direct your request to Velindre University NHS Trust, which delivers cancer treatment on behalf of the Health Board.
3. We do not hold the information requested in points 3a-3c. You may wish to direct your request to Velindre University NHS Trust, which delivers cancer treatment on behalf of the Health Board.